CClinicalTrials.gg
Sign In
CompletedNCT02495467Updated Feb 12, 2020Results posted

Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)

A Phase 2 interventional study of Glyceryl trinitrate and MED Placebo in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Futura Medical Developments Ltd. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects self-diagnosed with erectile dysfunction (ED) immediately before sexual intercourse.

Read the detailed description

This randomised, double-blind, placebo-controlled cross-over study is designed to evaluate the efficacy and safety of MED2005, a topically applied glyceryl trinitrate (GTN) gel administered to the penis of male subjects immediately before sexual intercourse. Subjects will be male aged between 18 and 70 years of age self-diagnosed with ED. Treatment requires the topical application of a pea sized volume (approximately 300 mg) of a 0.2% (w/w) gel to deliver a dose of 0.6 mg GTN to the glans of the penis. A total of 192 eligible subjects are planned to be enrolled into the study. Subjects will be screened for eligibility during the screening period (Day -45 to Day -2), provide a history of their ED treatments and those deemed eligible and who have a female consenting partner will participate in a run-in-period and two treatment periods (treatment period 1 and 2). The International Index for Erectile Function (IIEF) question 1 -5 and 15 will be used to determine pre-screening eligibility for the subject online. A score of 25 or less will be acceptable for inclusion to the run-in-period. Screening (visit 1) will be conducted over 1 day or may be divided into more than 1 day if wash-out of prior medications is needed. The screening period is applicable for visit 1 Informed consent will be signed by both partners before a couple can be admitted to the study. There will also be a subject and partner training requirement to ensure that the product is applied in an appropriate manner. After refraining from using other ED treatments for at least a period of a week, in the run-in-period (visit 2), subjects and their female partners will make at least 4 intercourse attempts (with a minimum of 1 attempt per week) during a 4 week (± 1 week) period. The subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt and at the end of the run-in period. Subjects who cannot comply with the minimum number of sexual attempts verified by completed Sexual Event Profile (SEP) or exceed 25 on the IIEF question 1 -5 and 15 will be excluded from the study. Scores generated from the run-in period will be used as an established baseline in the planned analyses. The run-in period will be completed prior to randomisation and dosing.

In treatment period 1 (visit 3 and visit 4), subjects will be allocated to receive either placebo or MED2005 (0.6 mg GTN) according to a pre-defined randomisation schedule. After refraining from using other ED treatments for at least a period of a week, subjects and their female partner will be trained in the application of the test article and asked to apply the test article immediately prior to sexual intercourse, and to make at least 4 intercourse attempts during a 4 week (± 1 week) period. The subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt, and again at the end of each treatment period. Subjects will be asked to return to the Clinical Pharmacology Unit (CPU) after 4 weeks' (± 1 week) to return used and unused test article from the first treatment period, to enable the clinical staff to check compliance and to assess their health status, including assessment of any Adverse Event (AE). At the end of treatment period 1 (visit 4), tubes will be weighed to ensure subject compliance.

Following a 1 week treatment-free cross-over period, the subjects will enter into treatment period 2.

In treatment period 2 (visit 5 and visit 6), subjects will be issued with the alternative test article, either placebo or MED2005 (0.6 mg GTN) according to the pre-defined randomisation code. Training on the application of the test article will be reinforced / repeated and the subject or their female partner will be asked to apply the test article immediately prior to sexual intercourse on at least 4 separate occasions during a 4-week period. After each intercourse attempt the subjects and their partners will be asked to complete questionnaires online to record their experiences after each sexual intercourse attempt, and again at the end of each treatment period.. Subjects will be asked to return to the CPU after 4 weeks' (± 1 week) time to return used and unused test article from the second treatment period, to enable the clinical staff to check compliance and to assess their health status, including assessment of any AEs. At the end of treatment period 2 (visit 6), tubes will be weighed to ensure subject compliance.

Subjects and their female partners will be followed up at 7 day's ± 2 days (visit 7) after the outpatient visit on week 4 of treatment period 2, as necessary, to follow up any on-going AEs.

02

Conditions studied

  • Erectile Dysfunction

Browse trials for

03

In context

Erectile Dysfunction

682 studies on the registry are indexed under Erectile Dysfunction; 116 are open to participants now.

This study's enrollment of 232 is above the median of 72 across 541 interventional studies indexed under Erectile Dysfunction.

Browse Erectile Dysfunction studies →

Lead sponsor

Futura Medical Developments Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Male aged between 18 and 70 years of age inclusive.
  2. Confirmed self-diagnosis of ED for more than 3 months.
  3. IIEF question 1 -5 and 15 score of 25 or less will be acceptable for inclusion to the run-in period.
  4. Subject answers "yes" to the question "At home over the past 3 months, have you experienced at least some growth of your penis in response to: (1) mechanical stimulation, or (2) visual stimulation?"
  5. In a continuous heterosexual relationship for at least 6 months prior to screening.
  6. Documented written informed consent from both subject and his female partner.

  7. Both partners must agree to use one of the acceptable methods of contraception listed below:

    • Occlusive cap (diaphragm or cervical/vault caps).
    • Surgical sterilisation (vasectomy with documentation of azoospermia).
    • The female partner uses oral contraceptives, injectable progesterone or subdermal implants.
    • The female partner uses medically prescribed topically-applied transdermal contraceptive patch.
    • The female partner has undergone documented tubal ligation (female sterilisation).
    • The female partner has undergone documented placement of an Intra Uterine Device (IUD).
  8. Both partners are capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, psychiatric, or other disease.
  2. Any history of an unstable medical or psychiatric condition or using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
  3. Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or delegate at screening.
  4. Any presence of chronic indwelling urethral catheterization or penile anatomical abnormalities (e.g. penile fibrosis) that would significantly impair erectile function.
  5. Any history of operations for Peyronie's disease.
  6. Primary hypoactive sexual desire or any history of hypogonadism
  7. Any history of radical prostatectomy.
  8. Any history of severe / uncontrolled diabetes.
  9. Subjects taking two or more anti-hypertensives for the treatment of blood pressure.
  10. Subjects with nursing partners, known pregnant partners or wish to become pregnant during the course of the study.
  11. Confirmed positive results from urine drug screen or from the alcohol breath test at screening and on admission (Day -1).
  12. Subject has recent (last 12 months) clinical evidence of alcoholism or drug abuse.
  13. Subject has a positive screen for hepatitis B consisting of Hepatitis B surface antigen (HBsAG), hepatitis C antibody, and human immunodeficiency virus (HIV).
  14. Any clinically significant abnormal laboratory, vital signs or other safety findings at screening or on admission.
  15. Subjects unwilling to cease use of vacuum devices, intracavernosal injection, Viagra ® or other therapy for ED.
  16. Unwillingness of the subject to agree to make four attempts at sexual intercourse on four separate days during each treatment period.
  17. Any history of unresponsiveness to Viagra ® treatment due to lack of efficacy with sexual stimulation after multiple attempts of sexual intercourse, or significant side effects excluding visual disturbances of Viagra ®.
  18. Less than 4 attempts at sexual intercourse or high IIEF scores (> 25) during the run-in period.
  19. Any known hypersensitivity to any component of the investigational product.
  20. Subjects who are illiterate or are unable to understand the language in which the online questionnaires are available.
  21. Subject has received any investigational product during the 90 days prior to dosing for this study.
  22. Subject or their partner cannot communicate reliably with the Investigator.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    MED Placebo then MED2005

    Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).

    Drug: Glyceryl trinitrate · Drug: MED Placebo

  • Experimental
    MED2005 then MED Placebo

    Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).

    Drug: Glyceryl trinitrate · Drug: MED Placebo

Interventions

  • DrugGlyceryl trinitrate

    At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks

    Also known as: MED2005

  • DrugMED Placebo

    At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks

    Also known as: MED2005 Vehicle

06

What researchers measure

Primary outcomes

  1. Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)

    Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of the treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-30, a lower score is regarded as more severe.

    Time frame: 4 Weeks

Secondary outcomes

  1. Orgasmic Function Domain Score of the International Index of Erectile (IIEF)

    Orgasmic function domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-10, a lower score is regarded as having a worse outcome.

    Time frame: 4 Weeks

  2. Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)

    Sexual desire domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.

    Time frame: 4 Weeks

  3. Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

    Intercourse satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 0-15, a lower score is regarded as having a worse outcome.

    Time frame: 4 Weeks

  4. Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

    Overall satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.

    Time frame: 4 weeks

  5. Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1

    SEP Question 1: "Were you able to achieve at least some erection (some enlargement of the penis)?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

    Time frame: 4 Weeks

  6. Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2

    SEP Question 2: "Were you able to insert your penis into your partner's vagina?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

    Time frame: 4 Weeks

  7. Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3

    SEP Question 3: "Did your erection last long enough for you to have successful intercourse?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

    Time frame: 4 Weeks

  8. Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4

    SEP Question 4: "Were you satisfied with the hardness of your erection?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

    Time frame: 4 Weeks

  9. Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5

    SEP Question 5: "Were you satisfied overall with this sexual experience?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

    Time frame: 4 Weeks

  10. Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1

    GAQ Question 1: "Has the treatment you have been taking improved your erectile function?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).

    Time frame: 4 Weeks

  11. Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2

    GAQ Question 2: "Has the treatment improved your ability to engage in sexual activity?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).

    Time frame: 4 Weeks

07

Results

Posted Jan 29, 2020

Participant flow

First Intervention (4 Weeks)
Participant flow — First Intervention (4 Weeks)
MilestoneMED Placebo Then MED2005MED2005 Then MED Placebo
Started114118
Completed114118
Not completed00
Washout (1 Week)
Participant flow — Washout (1 Week)
MilestoneMED Placebo Then MED2005MED2005 Then MED Placebo
Started114118
Completed112116
Not completed22
Second Intervention (4 Weeks)
Participant flow — Second Intervention (4 Weeks)
MilestoneMED Placebo Then MED2005MED2005 Then MED Placebo
Started112116
Completed112113
Not completed03

Outcome measures

PrimaryErectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)

Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of the treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-30, a lower score is regarded as more severe.

Time frame:
4 Weeks
Reported as:
Mean · score on a scale
Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)
score on a scaleMED PlaceboMED2005
Erectile Function (EF) Domain Score of the International Index of Erectile Function (IIEF)18.5 ± 6.719.6 ± 7.5
Statistical analysis
  • MED Placebo vs MED2005 · Mixed Models Analysis · p = 0.0132 · Mean difference (final values): 1.03 · 95% CI 0.22 to 1.84
SecondaryOrgasmic Function Domain Score of the International Index of Erectile (IIEF)

Orgasmic function domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 1-10, a lower score is regarded as having a worse outcome.

Time frame:
4 Weeks
Reported as:
Mean · score on a scale
Orgasmic Function Domain Score of the International Index of Erectile (IIEF)
score on a scaleMED PlaceboMED2005
Orgasmic Function Domain Score of the International Index of Erectile (IIEF)6.6 ± 2.67.0 ± 2.8
Statistical analysis
  • MED Placebo vs MED2005 · Mixed Models Analysis · p = 0.0122 · Mean difference (final values): 0.41 · 95% CI 0.09 to 0.73
SecondarySexual Desire Domain Score of the International Index of Erectile Function (IIEF)

Sexual desire domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.

Time frame:
4 Weeks
Reported as:
Mean · score on a scale
Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)
score on a scaleMED PlaceboMED2005
Sexual Desire Domain Score of the International Index of Erectile Function (IIEF)7.1 ± 1.87.5 ± 1.8
Statistical analysis
  • MED Placebo vs MED2005 · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 0.39 · 95% CI 0.21 to 0.57
SecondaryIntercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

Intercourse satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 0-15, a lower score is regarded as having a worse outcome.

Time frame:
4 Weeks
Reported as:
Mean · score on a scale
Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
score on a scaleMED PlaceboMED2005
Intercourse Satisfaction Domain Score of the International Index of Erectile Function (IIEF)8.6 ± 2.89.0 ± 2.8
Statistical analysis
  • MED Placebo · Mixed Models Analysis · p = 0.0055 · Mean difference (final values): 0.41 · 95% CI 0.12 to 0.69
SecondaryOverall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)

Overall satisfaction domain of the International Index of Erectile Function (IIEF) questionnaire. This will be measured at the end of treatment periods of 4 weeks (+/- 1 week). The minimum and maximum values are 2-10, a lower score is regarded as having a worse outcome.

Time frame:
4 weeks
Reported as:
Mean · score on a scale
Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)
score on a scaleMED PlaceboMED2005
Overall Satisfaction Domain Score of the International Index of Erectile Function (IIEF)6.6 ± 2.27.1 ± 2.3
Statistical analysis
  • MED Placebo vs MED2005 · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.48 · 95% CI 0.20 to 0.76
SecondaryPercentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1

SEP Question 1: "Were you able to achieve at least some erection (some enlargement of the penis)?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

Time frame:
4 Weeks
Reported as:
Mean · percentage of yes responses
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 1
percentage of yes responsesMED PlaceboMED2005
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 186.93 ± 26.2287.24 ± 26.47
Statistical analysis
  • MED Placebo vs MED2005 · Generalized Linear Mixed Model · p = 0.7999 · Means ratio: 0.995 · 95% CI 0.960 to 1.032
SecondaryPercentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2

SEP Question 2: "Were you able to insert your penis into your partner's vagina?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

Time frame:
4 Weeks
Reported as:
Mean · percentage of yes responses
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 2
percentage of yes responsesMED PlaceboMED2005
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 275.37 ± 34.9175.53 ± 36.49
Statistical analysis
  • MED Placebo vs MED2005 · Generalized Linear Mixed Model · p = 0.6746 · Means ratio: 0.989 · 95% CI 0.937 to 1.043
SecondaryPercentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3

SEP Question 3: "Did your erection last long enough for you to have successful intercourse?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

Time frame:
4 Weeks
Reported as:
Mean · percentage of yes responses
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 3
percentage of yes responsesMED PlaceboMED2005
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 352.64 ± 38.8157.32 ± 39.40
Statistical analysis
  • MED Placebo vs MED2005 · Generalized Linear Mixed Model · p = 0.0959 · Means ratio: 1.075 · 95% CI 0.987 to 1.170
SecondaryPercentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4

SEP Question 4: "Were you satisfied with the hardness of your erection?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

Time frame:
4 Weeks
Reported as:
Mean · percentage of yes responses
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 4
percentage of yes responsesMED PlaceboMED2005
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 428.97 ± 33.1242.91 ± 41.0
Statistical analysis
  • MED Placebo vs MED2005 · Generalized Linear Mixed Model · p = <0.0001 · Means ratio: 1.522 · 95% CI 1.267 to 1.829
SecondaryPercentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5

SEP Question 5: "Were you satisfied overall with this sexual experience?". Answered yes/no after each intercourse event during treatment periods of 4 weeks (+/- 1 week). Assessed as a percentage of yes responses in each period.

Time frame:
4 Weeks
Reported as:
Mean · percentage of yes responses
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 5
percentage of yes responsesMED PlaceboMED2005
Percentage of Affirmative Responses to Sexual Encounter Profile (SEP) Question 536.88 ± 36.9848.23 ± 40.87
Statistical analysis
  • MED Placebo vs MED2005 · Generalized Linear Mixed Model · p = 0.0005 · Means ratio: 1.320 · 95% CI 1.128 to 1.545
SecondaryNumber of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1

GAQ Question 1: "Has the treatment you have been taking improved your erectile function?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).

Time frame:
4 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1
ParticipantsMED PlaceboMED2005
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 15694
Statistical analysis
  • MED Placebo vs MED2005 · Prescott Test (Exact) · p = <0.0001
SecondaryNumber of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2

GAQ Question 2: "Has the treatment improved your ability to engage in sexual activity?". Answered yes/no after each treatment period of 4 weeks (+/- 1 week).

Time frame:
4 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2
ParticipantsMED PlaceboMED2005
Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 25485
Statistical analysis
  • MED Placebo vs MED2005 · Prescott Test (Exact) · p = 0.0003

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MED Placebo0/227 (0%)0/227 (0%)15/227 (6.6%)
MED20050/229 (0%)0/229 (0%)28/229 (12.2%)
Most frequent other events
Most frequent other events
EventMED PlaceboMED2005
HeadacheNervous system disorders7/22718/229
NasopharyngitisInfections and infestations11/22713/229

Baseline characteristics

Safety Set. A total of 231 subjects made use of the medication at least once and were included in the safety set.

Age, Continuous
Age, Continuous(years)MED Placebo Then MED2005MED2005 Then MED PlaceboTotal
Mean42.7 ± 13.743.3 ± 14.743.0 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)MED Placebo Then MED2005MED2005 Then MED PlaceboTotal
Female000
Male114117231
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MED Placebo Then MED2005MED2005 Then MED PlaceboTotal
Asian549
Black or African American71017
White9797194
Other5611
Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF)
Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF)(score on a scale)MED Placebo Then MED2005MED2005 Then MED PlaceboTotal
Mean17.1 ± 5.917.1 ± 5.517.1 ± 5.7
08

Study locations

1 site
  • Richmond Pharmacology Ltd.
    Croydon, Surrey CR7 7YE, United Kingdom
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02495467
Lead sponsor
Futura Medical Developments Ltd.
Collaborators
Richmond Pharmacology Limited
Responsible party
Sponsor
First posted
Jul 13, 2015
Start date
May 15, 2015
Primary completion
Jul 30, 2016
Completion
Jul 30, 2016
Results posted
Jan 29, 2020
Last update
Feb 12, 2020

Study contacts

Tim J Holland, MSc
study director · Futura Medical Developments Ltd.
Jörg Täubel, MD FFPM
principal investigator · Richmond Pharmacology Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Erectile Dysfunction→

Other studies from this sponsor

Futura Medical Developments Ltd.

Start the discussion